Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Pharmaceuticals (Basel, Switzerland)|January 28, 2014
From single target to multitarget/network therapeutics in Alzheimer's therapyHailin Zheng, Mati Fridkin, Moussa Youdim
Perspectives in Medicinal Chemistry|March 4, 2015
New approaches to treating Alzheimer's diseaseHailin Zheng, Mati Fridkin, Moussa Youdim
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|December 27, 2008
Multifunctional pharmacotherapy: what can we learn from study of selective serotonin reuptake inhibitor augmentation of antipsychotics in negative-symptom schizophrenia?Henry Silver, Yael Chertkow, Orly Weinreb, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|June 6, 2003
A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's diseaseMarta Weinstock, Elena Gorodetsky, Tatyana Poltyrev, et al.
The International Journal of Neuropsychopharmacology|January 7, 2011
SSRI augmentation of antipsychotic alters expression of GABA(A) receptor and related genes in PMC of schizophrenia patientsHenry Silver, Ehud Susser, Lena Danovich, et al.
Scientific Reports|September 2, 2016
Inhibition of caspase-9 aggravates acute liver injury through suppression of cytoprotective autophagyRui Guo, Bin Lin, Jing Fei Pan, et al.
Journal of Neural Transmission (Vienna, Austria : 1996)|March 20, 2023
The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson's diseaseToshiharu Nagatsu, Akira Nakashima, Hirohisa Watanabe, et al.
Journal of Cardiovascular Pharmacology|April 23, 2015
TVP1022: A Novel Cardioprotective Drug Attenuates Left Ventricular Remodeling After Ischemia/Reperfusion in PigsAssaf Malka, David Meerkin, Yaron D Barac, et al.
Pageof 2